In an interview with PharmaShots, Dr. Philip Mease, MD, Seattle Rheumatology Associates shares insights on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in The Lancet Rheumatology Shots: The […]readmore
In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen’s commitment to advance research in rheumatic disease. Shots: Janssen presented […]readmore
Shots: The approval is based on P-lll DISCOVER-1 & -2 study assessing Tremfya (100mg q4w and q8w) vs PBO in 381 & 739 patients with active PsA who had an […]readmore
Shots: The CHMP’s positive opinion is based on P-III DISCOVER-1 & -2 studies assessing guselkumab (100 mg, q4w/q8w) vs PBO in 381 & 739 patients with active PsA & patients […]readmore
Shots: The P-II GALAXI 1 study involves assessing of Tremfya vs PBO in patients with mod. to severely active CD with intolerance to conventional therapies. In interim analyses, patients were […]readmore
Shots: The approval is based on two pivotal P-III clinical trials (DISCOVER-1 and DISCOVER-2) assessing Tremfya (100 mg, SC, q8w) following two starter doses @0 & 4wks. vs PBO in […]readmore
Shots: The P-III DISCOVER 1 & 2 studies involves assessing of Tremfya (q4w/q8w, SC) vs PBO in 381 & 739 patients with active psoriatic arthritis including those previously treated with […]readmore
Shots: The sBLA is based on two P-III DISCOVER-1 & 2 studies assessing Tremfya (SC) in 381 & 739 patients with active PsA including prior treated patients with anti-TNF therapy […]readmore
Shots: The P-III DISCOVER 1 & 2 studies results involve assessing of Tremfya vs PBO in 381 & 739 patients with PsA prior treated with anti-TNF biologics & bio-naive candidates […]readmore
Shots: The approval is based on P-III study results assessing Tremfya (guselkumab, 100mg) vs PBO in 78 patients with moderate-to-severe plaque psoriasis P-III ORION study: IGA score of 0/1 or […]readmore
Copyright © 2020 Digiqole. All Right Reserved.